Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma × dostarlimab × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Endometrial Neoplasms 7 Ovarian Neoplasms 6 Neoplasms 6 Uterine Cervical Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 3 Rectal Neoplasms 3 Pancreatic Neoplasms 3 Neoplasm Metastasis 3 Head and Neck Neoplasms 3 Colonic Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Lung Neoplasms 2 Fallopian Tube Neoplasms 2 Carcinoma, Neuroendocrine 2 Breast Neoplasms 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Turcot syndrome 1 Triple Negative Breast Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma, Clear Cell 1 Sarcoma 1 Recurrence 1 Penile Neoplasms 1 Pathologic Complete Response 1 Neoplasms, Second Primary 1 Multiple Myeloma 1 Mesothelioma, Malignant 1 Mesothelioma 1 Melanoma 1

Interventions

Cisplatin 19 Paclitaxel 15 Carboplatin 15 Gemcitabine 12 pembrolizumab 11 Fluorouracil 8 Specimen Handling 7 Radiotherapy 7 Nivolumab 6 Magnetic Resonance Spectroscopy 6 Docetaxel 6 cemiplimab 5 Sunitinib 5 Platinum 5 Oxaliplatin 5 Everolimus 5 Cyclophosphamide 5 Capecitabine 5 durvalumab 4 anlotinib 4 Radiotherapy, Intensity-Modulated 4 Pemetrexed 4 Drug Therapy 4 Cetuximab 4 1,2-diaminocyclohexaneplatinum II citrate 4 padeliporfin 3 epothilone B 3 atezolizumab 3 Panitumumab 3 Leucovorin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06317311 2025-07-25

RUBY-J

GlaxoSmithKline

Phase 2 Active not recruiting

Carcinoma, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡